{"id":"W1997880566","doi":"10.1016/s1474-4422(14)70068-7","title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","year":2014,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":395,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"IC Design Education Center; Biogen","keywords":"Medicine; Placebo; Multiple sclerosis; Internal medicine; Clinical endpoint; Expanded Disability Status Scale; Relapsing remitting; Adverse effect; Gastroenterology; Dosing; Pegylated interferon; Randomized controlled trial; Immunology; Ribavirin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004124814,0.002507095,0.005488447,0.00084509,0.0007116352,0.0009304273,0.001128009,0.003243222,0.006545107],"category_scores_gemma":[0.002427213,0.001237228,0.003129922,0.0007723575,0.001870312,0.001955982,0.0007529889,0.002870759,0.001239772],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000834994,"about_ca_system_score_gemma":0.001567607,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001442077,"about_ca_topic_score_gemma":0.001895464,"domain_scores_codex":[0.9985794,0.000713942,0.0001138273,0.0001967701,0.0001512074,0.0002449511],"domain_scores_gemma":[0.998315,0.0005329044,0.0003440097,0.0002312654,0.0001056707,0.0004711156],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9896321,0.00275332,0.0001669279,0.000261624,0.0003671144,0.00001900923,0.00003131051,0.0001343392,0.001135525,0.00004984308,0.0002096006,0.005239296],"study_design_scores_gemma":[0.9796412,0.01932012,0.0005413932,0.000009137604,0.0001289273,0.00001126089,0.000005570783,0.0000745679,0.00009006158,0.00005050248,0.0001208385,0.000006462622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830184,0.005028054,0.001238161,0.0004678702,0.0005437963,0.006671732,0.001244084,0.0001892352,0.001598738],"genre_scores_gemma":[0.967828,0.004977164,0.004980105,0.001918405,0.001073411,0.01261251,0.001995721,0.0000671204,0.004547486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006545107,"threshold_uncertainty_score":0.02189553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1893065369257501,"score_gpt":0.385908890795452,"score_spread":0.1966023538697019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}